We rank companies based on fund manager, research analyst and news sentiment
BDSX stock icon

Biodesix, Inc. Common Stock
BDSX

$1.23
4.84%
 

About: Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Employees: 217

0
Funds holding %
of 6,474 funds
Analysts bullish %
0
News positive %
of 3 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

33% more call options, than puts

Call options by funds: $1.47K | Put options by funds: $1.1K

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

18% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 11

11% more capital invested

Capital invested by funds: $30.5M [Q3] → $33.8M (+$3.3M) [Q4]

3% more funds holding

Funds holding: 37 [Q3] → 38 (+1) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

3.09% less ownership

Funds ownership: 21.78% [Q3] → 18.69% (-3.09%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$3.5
185%
upside
Avg. target
$3.5
185%
upside
High target
$3.5
185%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Canaccord Genuity
Kyle Mikson
185%upside
$3.5
Buy
Reiterated
4 Mar 2024
Canaccord Genuity
Kyle Mikson
185%upside
$3.5
Buy
Reiterated
7 Dec 2023

Financial journalist opinion

Based on 3 articles about BDSX published over the past 30 days